The Center for Molecular Imaging and Therapy is a research organization in Shreveport devoted to developing novel radiopharmaceuticals which can lead to improved diagnosis and therapy for a wide range of diseases. CMIT actively performs radiopharmaceutical and translational research as well as clinical imaging.

About CMIT

Formerly the PET Imaging Center (PETIC), CMIT was established in 1995 by BRF as one of the first non-academic, full-service PET imaging centers in the United States and the first in Louisiana. Positron Emission Tomography (PET) is a molecular imaging technique that produces images that assist in the early diagnosis and therapeutic assessment of diseases which may lead to better patient outcomes and reduced medical costs.

In 2013, PETIC expanded its mission and services to become CMIT. CMIT seeks to be a national resource that will provide Louisiana residents with increased access to state-of-the-art diagnostic and therapeutic technologies, as well as increasing the clinical and pre-clinical research capacity of local and regional research institutions.


CMIT has been engaged in multiple clinical trials, ranging from treating prostate cancer patients with advanced experimental radiotherapy, to localizing endocrine abnormalities leading to hyperinsulism in infants, and imaging patients with Alzheimer’s and Parkinson’s disease.

Additionally, CMIT provides radiopharmaceutical and imaging support for clinical trials performed at Ochsner LSU Health in Shreveport and other centers throughout the nation. CMIT strengthens Shreveport and the surrounding areas as a hub for medical treatments and research.


Since 1995, CMIT has performed over 9,700 scans, valued at $30.6 million, free of charge to indigent patients, primarily to Louisiana residents. Since 1994, CMIT has performed over 46,000 clinical procedures and has helped to establish PET imaging as the standard of care in the fields of oncology and neurology.


Currently CMIT manufactures radiopharmaceuticals that are used for diagnosis and therapy assessment for oncology, cardiology, and neuroimaging. CMIT has continued to expand radiopharmaceutical availability through enhanced production capabilities and expanded radiopharmaceutical inventory.


CMIT is expanding its footprint on the Shreveport Healthcare and Technology Corridor with a new 20,000 sq. ft. facility at the corner of Kings Highway and Mansfield Road. The new CMIT will include an expanded radiopharmaceutical production operation, patient imaging services and a clinical and translational research program. The $19.5 million expansion project is expected to open in 2021.


To find out more about the Center for Molecular Imaging and Therapy, follow the link to the official website.


Dr. Stephen Lokitz

Interim Executive Director

318-716-4040  •

Latest Videos

"We believe if we continue to bring jobs here, people will come, and Shreveport will thrive."
-John F. George Jr., M.D., BRF President and CEO

BRF's 2021 Annual Meeting video showcases our various initiatives in economic development and some of the exciting work BRF and its collaborators are doing to diversify and grow our region's economy.

Learn more about BRF and its initiatives at our YouTube channel.


BRF releases digital-only October Quarterly Report

Get caught up with BRF in the new Quarterly Report for Oct 2022.

National Cancer Institute designation and improved cancer outcomes will require statewide collaboration

The work is already underway in North Louisiana Special column byJohn F. George Jr., MD, BRF President and CEOIn late...

More than $300M to be invested in Shreveport Healthcare and Development Corridor

In August, leaders of the City of Shreveport, SporTran, BRF, LSU Health Shreveport, Ochsner LSU Health Shreveport and the Louisiana...


Diversify and grow our region’s economy.


Operate as a catalyst to expand and develop research, entrepreneurship and high-growth businesses in our region.


Innovation. Collaboration. Problem Solving. Bold Action.

Stay Updated

Sign up to join the BRF news list to get BRF news and updates delivered to your inbox.